Skip to main content
. Author manuscript; available in PMC: 2011 Jan 1.
Published in final edited form as: Pediatr Blood Cancer. 2010 Jan;54(1):47–54. doi: 10.1002/pbc.22267

Figure 1.

Figure 1

Event Free Survival (EFS) of patients treated with ABT-751. The median EFS was 9.3 weeks in children with neuroblastoma (NBL) and 3.3 weeks in children with other solid tumors (P<0.0001)